Hey @stephencca, I agree with some of what you say, not all the good things that are happening with the company now, were hatched by this management. The sale of Metrics (unfortunate but very necessary) was done by the previous CEO and current Chairman, swiftly and for a good price, so kudos to them. Also the DTC strategy for dermatology was also hatched by the previous CEO but the execution was poor resulting in negative revenue in 1HF 2023. As far as Womens Health products, the previous CEO was responsible for buying Nexstellis for a huge price and committing the company to large launch costs and the launch was poorly executed, without the purchase of the TherapeuticsMD products by current CEO, Women's Health would be years away from delivering a profit.
And finally, it's not my style to put other investors down for poorly timed decisions they made and I hope that this mngt team can deliver a profit for them.
- Forums
- ASX - By Stock
- MYX
- Ann: Mayne Pharma presentation at JP Morgan Healthcare Conference
Ann: Mayne Pharma presentation at JP Morgan Healthcare Conference, page-10
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MYX (ASX) to my watchlist
(20min delay)
|
|||||
Last
$3.90 |
Change
0.020(0.52%) |
Mkt cap ! $333.4M |
Open | High | Low | Value | Volume |
$3.89 | $3.94 | $3.88 | $35.63K | 9.113K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 222 | $3.90 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$3.91 | 2598 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 265 | 3.890 |
7 | 1910 | 3.880 |
5 | 2037 | 3.870 |
8 | 7025 | 3.860 |
5 | 2349 | 3.850 |
Price($) | Vol. | No. |
---|---|---|
3.900 | 1217 | 12 |
3.910 | 3774 | 13 |
3.920 | 1958 | 7 |
3.930 | 1156 | 5 |
3.940 | 4164 | 5 |
Last trade - 12.10pm 09/08/2024 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |